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Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to create rHPIV1-P(C), a virus in
which expression of the C proteins (C, C, Y1, and Y2) was silenced without affecting the amino acid sequence
of the P protein. Infectious rHPIV1-P(C) was readily recovered from cDNA, indicating that the four C
proteins were not essential for virus replication. Early during infection in vitro, rHPIV1-P(C) replicated as
efficiently as wild-type (wt) HPIV1, but its titer subsequently decreased coincident with the onset of an extensive
cytopathic effect not observed with wt rHPIV1. rHPIV1-P(C) infection, but not wt rHPIV1 infection, induced
caspase 3 activation and nuclear fragmentation in LLC-MK2 cells, identifying the HPIV1 C proteins as
inhibitors of apoptosis. In contrast to wt rHPIV1, rHPIV1-P(C) and rHPIV1-CF170S, a mutant encoding an
F170S substitution in C, induced interferon (IFN) and did not inhibit IFN signaling in vitro. However, only
rHPIV1-P(C) induced apoptosis. Thus, the anti-IFN and antiapoptosis activities of HPIV1 were separable:
both activities are disabled in rHPIV1-P(C), whereas only the anti-IFN activity is disabled in rHPIV1-CF170S.
In African green monkeys (AGMs), rHPIV1-P(C) was considerably more attenuated than rHPIV1-CF170S,
suggesting that disabling the anti-IFN and antiapoptotic activities of HPIV1 had additive effects on attenuation
in vivo. Although rHPIV1-P(C) protected against challenge with wt HPIV1, its highly restricted replication
in AGMs and in primary human airway epithelial cell cultures suggests that it might be overattenuated for use
as a vaccine. Thus, the C proteins of HPIV1 are nonessential but have anti-IFN and antiapoptosis activities
required for virulence in primates.
Human parainfluenza virus type 1 (HPIV1) is a member of
the Paramyxoviridae family, which includes a number of other
medically important human pathogens, such as HPIV2 and -3,
respiratory syncytial virus (RSV), measles virus, mumps virus,
and human metapneumovirus (33). The HPIVs are enveloped,
nonsegmented, single-stranded, negative-sense RNA viruses
that are classified in the genera Respirovirus (HPIV1 and
HPIV3) and Rubulavirus (HPIV2). HPIV1, -2, and -3 are sig-
nificant respiratory pathogens for infants and young children,
with clinical manifestations ranging from mild disease, includ-
ing rhinitis and pharyngitis, to more-severe disease, including
croup, bronchiolitis, and pneumonia (12, 24, 25, 33, 44, 55).
The contribution of HPIV infections to pediatric respiratory
hospitalizations varies between studies and ranges from 7 to
21% overall for HPIV1, -2, and -3. The HPIVs collectively are
the second leading cause of pediatric hospitalizations for viral
respiratory disease, behind RSV and ahead of influenza (31,
33, 47). A licensed vaccine is currently not available for the
prevention of HPIV disease, but experimental live attenuated
candidate vaccines are under development for HPIV1, -2, and
-3, with those for HPIV3 in clinical trials (3, 5, 22, 32, 34, 51).
The HPIV1 genome is 15,600 nucleotides in length and
contains six genes in the order 3-N-P/C-M-F-HN-L-5 (50).
Each gene encodes a single protein, with the exception of the
P/C gene that encodes the phosphoprotein P in one open
reading frame (ORF) and up to four accessory C proteins, C,
C, Y1, and Y2, in a second, overlapping ORF. The synthesis of
the C proteins initiates at four separate translational start
codons in the C ORF in the order C, C, Y1, and Y2, and the
four proteins are carboxy coterminal (33). However, it is un-
clear whether the Y2 protein is actually expressed during
HPIV1 infection (54). C proteins are expressed by members of
the Respirovirus, Morbillivirus, and Henipavirus genera, but not
by viruses that belong to the Rubulavirus and Avulavirus gen-
era. The paramyxovirus C proteins studied to date are nones-
sential accessory proteins that contribute significantly to virus
replication and virulence in vivo (1, 30, 41, 42). The C proteins
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of Sendai virus (SeV), a member of the Respirovirus genus and
the closest homolog of HPIV1, are the most extensively char-
acterized.
The C proteins of SeV have been shown to have multiple
functions that include inhibition of host innate immunity
through antagonism of interferon (IFN) induction and/or sig-
naling (17, 20, 38); regulation of viral mRNA synthesis by
binding to the L polymerase protein (10, 13, 27, 42, 64); par-
ticipation in virion assembly and budding via an interaction
with AIP1/Alix, a cellular protein involved in apoptosis and
endosomal membrane trafficking (23, 28, 56); and regulation of
apoptosis (see below). SeV mutants containing deletions of all
four C proteins are viable but are highly attenuated in vitro and
in mice (19, 41, 42). To date, the HPIV1 C proteins have not
been as extensively studied as those of SeV. However, the
HPIV1 C proteins, like the SeV C proteins, play a role in
evasion of host innate immunity through inhibition of type I
IFN production and signaling (8, 65). Type I IFN was not
detected during infection with wild-type (wt) HPIV1 in A549
cells, a human epithelial lung carcinoma cell line, but was
induced during infection with a recombinant HPIV1 (rHPIV1)
mutant bearing an F170S amino acid substitution in C, desig-
nated rHPIV1-CF170S (65). Wt HPIV1, but not the rHPIV1-
CF170S mutant, inhibited the antiviral state induced by type I
IFN, most likely due to inhibition of STAT1 nuclear translo-
cation in human lung cells (8, 65).
Many viruses have evolved strategies to regulate host cell
apoptotic responses to virus infection (reviewed in reference
45). Apoptosis, a process of programmed cell death mediated
by the activation of a group of caspases, results in systematic
cellular self-destruction in response to a variety of stimuli (re-
viewed in reference 14). There are two major apoptotic path-
ways, the extrinsic and intrinsic pathways, which converge at a
step involving the activation of effector caspase 3. The activa-
tion of effector caspases, nuclear condensation and fragmen-
tation, and cell death are the final steps in the apoptosis path-
way. Viral proteins that are able to modulate the host
apoptotic response include proapoptotic viral proteins, such as
West Nile virus capsid protein (71) and bunyavirus NSs pro-
teins (11), and antiapoptotic viral proteins, such as RSV NS
proteins (6), Bunyamwera virus NSs (35), and Rift Valley fever
virus NSm protein (69). However, these studies are complex
and some viral proteins, such as influenza A virus NS1, have
been reported to have both pro- and antiapoptotic functions
(58, 73). SeV C proteins have been implicated in the regulation
of apoptosis, but their role in this process remains incompletely
defined (7, 26, 29, 39, 52). A role for HPIV1 proteins in
apoptosis has not been investigated to date.
In the present study, an rHPIV1 mutant was generated in
which the C protein ORF was modified by using reverse ge-
netics to preclude the expression of any of the four C proteins
while maintaining the expression of a wt P protein. This mu-
tant, designated rHPIV1-P(C), was evaluated for replication
in vitro and in vivo in order to determine (i) whether C was
essential for HPIV1 replication; (ii) what effect the deletion of
C protein expression had on the host response to virus infec-
tion; and (iii) whether a C protein deletion mutant had prop-
erties that warranted further development as a live attenuated
HPIV1 candidate vaccine. In contrast to wt HPIV1 (but similar
to rHPIV1-CF170S), rHPIV1-P(C) was found to induce a
robust IFN response. In addition, in contrast to wt HPIV1 (and
also in contrast to rHPIV1-CF170S), rHPIV1-P(C) induced a
potent apoptotic response. Both phenotypes appeared to con-
tribute to attenuation in African green monkeys (AGMs) and
in cultures of ciliated human airway epithelium (HAE).
MATERIALS AND METHODS
Cells and viruses. LLC-MK2 cells (ATCC CCL 7.1) and HEp-2 cells (ATCC
CCL 23) were maintained in Opti-Mem I (Gibco-Invitrogen, Inc., Grand Island,
NY) supplemented with 5% fetal bovine serum (FBS) and gentamicin sulfate (50
g/ml). A549 cells (ATCC CCL-185) were maintained in F-12 nutrient mixture
(Ham) (Gibco-Invitrogen, Inc.) supplemented with 10% FBS, gentamicin sulfate
(50 g/ml), and L-glutamine (4 mM). Vero cells (ATCC CCL-81) were main-
tained in minimal essential medium (MEM; Gibco-Invitrogen, Inc.) supple-
mented with 10% FBS, gentamicin sulfate (50 g/ml), and L-glutamine (4 mM).
BHK-T7 cells, which constitutively express T7 RNA polymerase (9), were kindly
provided by Ursula Buchholz, NIAID, and were maintained in Glasgow MEM
(GMEM; Gibco-Invitrogen, Inc.) supplemented with 10% FBS, Geneticin (1
mg/ml), MEM amino acids, and L-glutamine (2 mM). Tracheobronchial HAE
cells were isolated from airway specimens of patients without underlying lung
disease provided by the National Disease Research Interchange (NDRI, Phila-
delphia, PA) or from excess tissue obtained during lung transplantation, pro-
vided by the University of North Carolina (UNC) Cystic Fibrosis Center Tissue
Culture Core under protocols approved by the UNC Chapel Hill Institutional
Review Board. Growth and differentiation of these cells on semipermeable
Transwell inserts at the air-liquid interface generated ciliated HAE, as previously
described (53). All infections were incubated at 32°C except where indicated
otherwise.
Biologically derived wt HPIV1 Washington/20993/1964, the parent of rHPIV1,
was isolated from a clinical sample in primary AGM kidney cells and passaged
two more times in primary AGM kidney cells (48) and once in LLC-MK2 cells
(2). This preparation has a wt phenotype in AGMs and will be referred to here
as wt HPIV1, but it was previously referred to as HPIV1LLC1 (2). The wt rHPIV1
referred to in this study also contains a mutation in the HN gene, HNT553A,
which has previously been shown not to have an effect on virus replication (1),
and wt rHPIV1 is therefore considered the equivalent of wt virus. Wt rHPIV1
was generated as previously described (2, 50, 65). Wt rHPIV1 was used in all
experiments, with the exception that the biological wt HPIV1 was used for the
hamster challenge and in the AGM studies, as indicated below. The generation
and characterization of the rHPIV1-CF170S mutant was also described previously
(2); this virus contains a single-nucleotide substitution in the P/C gene that
creates a phenylalanine-to-serine substitution at amino acid (aa) 170 (numbered
relative to the C protein) that affects all four C proteins and is silent in the P
protein. The medium used for the propagation and infection of wt HPIV1 and
rHPIV1 mutants in LLC-MK2 cells did not contain FBS but contained 1.2%
TrypLE Select, a recombinant trypsin (Gibco-Invitrogen, Inc.), in order to cleave
and activate the HPIV1 fusion (F) protein, as described previously (50). Purified
virus stocks were obtained by infection of LLC-MK2 cells, followed by centrif-
ugation and banding of virus containing supernatant in a discontinuous 30%/60%
(wt/vol) sucrose gradient, steps designed to minimize contamination with cellular
factors, especially IFN. Recombinant vesicular stomatitis virus expressing the
green fluorescent protein (VSV-GFP) was originally obtained from John Hiscott
(61). Stocks of VSV were propagated in Vero cells and sucrose purified as
indicated above.
Virus titers in samples were determined by 10-fold serial dilution of virus in
96-well LLC-MK2 monolayer cultures, using two or four wells per dilution. After
7 days of incubation, infected cultures were detected by hemadsorption with
guinea pig erythrocytes, as described previously (59). Virus titers are expressed
as log10 50% tissue culture infectious dose per ml (log10 TCID50/ml). VSV stock
titers were determined by plaque assay on Vero cells under an 0.8% methyl
cellulose overlay.
Antibodies. Polyclonal antisera directed against the HPIV1 C or P proteins
were generated by repeated immunization of rabbits with the following keyhole
limpet hemocyanin-conjugated peptides: (i) QMREDIRDQYLRMKTERW (aa
residues 153 to 170 of HPIV1 C; directed against the carboxyl-terminal region
of C, C, Y1, and Y2) for Skia-31 and (ii) RDPEAEGEAPRKQES (aa 10 to 24
of P) for Skia-2. Antisera were generated at Spring Valley Laboratories, Inc.
(Woodbine, MD). Two murine monoclonal antibodies directed against the
HPIV1 HN protein, designated 8.2.2.A and 4.5, were kindly provided by Yasu-
hiko Ito (37).
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Construction of mutant rHPIV1-P(C) cDNA. Nucleotide insertions, dele-
tions, and substitutions were introduced into the P/C gene of wt rHPIV1 (Fig.
1A) (49) in order to silence the expression of the C, C, Y1, and Y2 proteins
without affecting the P protein (Fig. 1B and C). The 93 nucleotides between the
P/C gene start signal and the P start codon, including the C start codon, were
deleted (Fig. 1B and C, mutation 2) and replaced with a 6-nucleotide insertion
to act as a “linker” (Fig. 1B and C, mutation 1). The sequence immediately
upstream of the P start codon was modified by the addition of the “linker”
CGA(ATG) to AAC(ATG) (nucleotide substitutions are underlined), making
the P start site more efficient by Kozak’s rules (40) and reducing translational
FIG. 1. Designing the HPIV1-P(C) viral cDNA. (A) The wt HPIV1 genome, shown 3 to 5, includes the P/C gene that encodes the phosphoprotein P
from one ORF and the four carboxy-coterminal C proteins, C, C, Y1 and Y2, from a second, overlapping ORF. The coding regions for these proteins are shown,
with the initiation and termination codons numbered according to the P/C gene sequence. (B and C) Various mutations were introduced into the HPIV1 P/C
gene to silence expression of the four C proteins without affecting the amino acid sequence of the P protein. Panel B shows the sequence of the upstream end
of the P/C gene, with the transcription gene start signal and the translational start signal for each protein boxed. Nucleotide (nt) substitutions and an insertion
in the rHPIV1-P(C) sequence are indicated in boldface, and a deletion is indicated with a dotted line. Conversion of the C start codon and stop codons are
indicated with the symbol v. These mutations are identified with circled numbers that correspond with a description in panel C of the effect of each mutation.
Briefly, 93 nt were deleted between the gene start signal and P start codon and replaced with a 6-nt spacer, CCCAAC (mutations 1 and 2), thus eliminating the
first 11 codons of C, including its start codon. The sequence immediately upstream of the P start codon was modified from CGA(ATG) to AAC(ATG), which
also optimizes the Kozak sequence and reduces translational initiation at the downstream start codons (mutation 1). The methionine start codon of the C protein
was converted to threonine (mutation 3), one stop codon was introduced downstream of the Y1 start codon (mutation 4), and two stop codons were introduced
downstream of the Y2 start codon (mutations 5 and 6). The arrows labeled “M” and “T” indicate unaltered Y1 and Y2. This cDNA was used to recover
infectious rHPIV1-P(C).
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initiation at the downstream start codons (Fig. 1B and C, mutation 1). The C
start codon was modified (ATG to ACG) (Fig. 1B and C, mutation 3), and three
codons were converted to stop codons, including one immediately downstream of
the Y1 start codon (TCA to TGA) which will affect all of the C proteins except
Y2 and two downstream of the Y2 start codon (TCG to TAG and TTG to TAG)
which will affect all of the C proteins (Fig. 1B and C, mutations 4, 5, and 6). All
of the introduced changes are silent in the P protein. These changes were
achieved by using a modified PCR mutagenesis protocol described elsewhere
(46) and an Advantage HF PCR kit (Clontech Laboratories, Palo Alto, CA). The
entire PCR-amplified gene product was sequenced by using a Perkin-Elmer ABI
3100 sequencer with a BigDye sequencing kit (Perkin-Elmer Applied Biosys-
tems, Warrington, United Kingdom) to confirm amplification of the desired
sequence containing the introduced changes. Full-length antigenomic cDNA
clones (FLCs) of HPIV1 containing the desired mutations were assembled in T7
polymerase-driven plasmids by using standard molecular cloning techniques
(50), and the region containing the introduced mutation in each FLC was se-
quenced as described above to confirm the presence of the introduced mutation
and absence of adventitious changes. Each virus was designed to conform to the
rule of six, i.e., the nucleotide length of each genome was designed to be an even
multiple of six (36), a requirement for efficient replication of HPIV1.
Recovery of infectious rHPIV1-P(C). rHPIV1-P(C) was recovered by using
a reverse genetics system similar to previously described methods (50) in
BHK-T7 cells constitutively expressing T7 polymerase (9) that were grown to 90
to 95% confluence in six-well plates. Cells were transfected with 5 g of the FLC,
0.8 g each of the N and P, and 0.1 g of the L support plasmids in a volume of
100 l of Opti-Mem per well. Transfection was carried out with Lipofectamine
2000 (Invitrogen, Inc., Carlsbad, CA) according to the manufacturer’s directions.
The transfection mixture was removed after a 24-h incubation period at 37°C.
Cells were then washed and maintained in GMEM supplemented with amino
acids and 1.2% TrypLE Select and transferred to 32°C. On day 2 following
transfection, the supernatant was harvested. Virus was amplified by passage on
LLC-MK2 cells and cloned biologically by two successive rounds of terminal
dilution using LLC-MK2 monolayers on 96-well plates (Corning Costar, Inc.,
Acton, MA). To confirm that rHPIV1-P(C) contained the appropriate muta-
tions and lacked adventitious mutations, viral RNA was isolated from infected
cell supernatants by using a QIAamp viral RNA mini kit (Qiagen, Inc., Valencia,
CA), reverse transcribed by using a SuperScript first-strand synthesis system
(Invitrogen, Inc., Carlsbad, CA), and amplified by using an Advantage HF cDNA
PCR kit (Clontech Laboratories). The viral genome was sequenced in its en-
tirety, confirming its sequence.
Western blotting. LLC-MK2 monolayers grown in six-well plates (Costar)
were mock infected or infected at an input multiplicity of infection (MOI) of 5
TCID50/cell with sucrose-purified wt rHPIV1 or rHPIV1-P(C). Cell lysates
were harvested 48 h postinfection (p.i.) with 200 l of 1 loading dye solution
sample buffer (Qiagen, Inc.) and purified on QIAshredder (Qiagen, Inc.) spin
columns. Ten microliters (for Skia-31 probing) or 6 l (for Skia-2 probing) of
each sample was reduced, denatured, and loaded onto 10-well 10% Bis-Tris gels
(Invitrogen, Inc.). Gels were run in morpholinepropanesulfonic acid (MOPS)
buffer (Invitrogen, Inc.), and protein was transferred onto polyvinylidene diflu-
oride membranes (Invitrogen, Inc.) and blocked overnight at 4°C in phosphate-
buffered saline (PBS)-Tween (0.1%) containing 3% bovine serum albumin
(BSA). The polyvinylidene difluoride membranes were incubated with 15 ml of
a 1:1,000 dilution of primary antibody in PBS-Tween with 1% BSA at room
temperature (RT) for 2 h and then were washed three times for 10 min with
PBS-Tween. Membranes were incubated for 1 h at RT with a 1:20,000 dilution
of peroxidase-labeled goat anti-rabbit immunoglobulin G (IgG) (KPL, Gaithers-
burg, MD) as the secondary antibody. After the membranes were washed three
times for 10 min with PBS-Tween, SuperSignal West pico chemiluminescent
substrate (Pierce, Rockford, IL) was added for 10 min at RT. Membranes were
developed on Kodak MR films (Kodak, Rochester, NY).
Kinetics of replication of rHPIV1-P(C). Wt rHPIV1 and rHPIV1-P(C)
were compared in multicycle growth curves. Confluent monolayer cultures of
LLC-MK2 cells in six-well plates were infected in triplicate at an MOI of 0.01
TCID50/cell. Virus adsorption was performed for 1 h in medium containing
trypsin. The inoculum was then removed, and cells were washed three times,
after which fresh medium containing trypsin was added and then harvested as the
day zero sample and replaced with fresh medium containing trypsin. On days 1
to 7 p.i., the entire supernatant was removed for virus quantitation and was
replaced with fresh medium containing trypsin. Supernatants containing virus
were frozen at 80°C, and virus titers (log10 TCID50/ml) were determined with
endpoints identified by hemadsorption. Cytopathic effect (CPE) was visually
monitored. The amount of CPE observed under the microscope was given a
score ranging from 1 to 5 based on the percentage of cells in the monolayer
showing CPE. A CPE of less than 20% of cells was scored as 1, 21 to 40% as 2,
41 to 60% as 3, 61 to 80% as 4, and 81 to 100% as 5.
Immunostaining and confocal microscopy. LLC-MK2 cells were seeded onto
24-well plates containing 12-mm glass coverslips, mock infected or infected with
rHPIV1-P(C) or wt rHPIV1 at an MOI of 10 TCID50/cell, and incubated for
72 h. Medium was removed, and coverslips were washed twice with PBS. Cells
were then fixed with 3% formaldehyde solution in PBS for 40 min at RT, washed
once with PBS, permeabilized with 0.1% Triton X-100 in PBS for 4 min at RT,
and washed twice with PBS prior to blocking with PBS containing 0.25% BSA
and 0.25% gelatin for 1 h at RT. HPIV1 HN staining was performed by using as
primary antibody a 1:4,000 dilution of a mixture of HPIV1-HN 8.2.2.A and
HPIV1-HN 4.5, two murine antibodies directed against the HPIV1 HN protein,
kindly provided by Yasuhiko Ito, Mie University School of Medicine, Mie, Japan.
After incubation at RT for 1 h, cells were washed twice with PBS and stained
with a 1:1,000 dilution of Texas Red-conjugated donkey anti-mouse IgG (Jack-
son Immunochemicals, West Grove, PA) as secondary antibody for 1 h at RT.
Activated caspase 3 was detected by using a 1:25 dilution of a fluorescein
isothiocyanate (FITC)-conjugated rabbit anti-human activated caspase 3 anti-
body (BD Pharmingen, San Jose, CA). Cells were washed twice with PBS and
immediately mounted onto slides with the 4,6-diamidino-2-phenylindole
(DAPI)-containing antifade reagent ProLong gold (Invitrogen, Inc.). Slides were
covered with foil, left to dry overnight at RT, and then stored at 20°C until
microscopy was performed on a Leica SP5 confocal microscope.
FACS analysis. LLC-MK2, Vero, or A549 cells in six-well plates were mock
infected or infected with wt rHPIV1 or rHPIV1-P(C) at an MOI of 5 TCID50/
cell. Cells were harvested at 24, 48, and 72 h p.i. by scraping cells into 2 ml of
fresh fluorescence-activated cell sorting (FACS) buffer (PBS, 1% FBS) and
pelleting at 1,200 rpm for 10 min at 4°C. Cells were resuspended in 1 ml of 3%
paraformaldehyde, fixed for 15 min on ice, and then rinsed twice in 3 ml FACS
buffer. Cells were permeabilized and stained with the following antibodies di-
luted in FACS buffer containing 0.1% Triton X-100: (i) rabbit anti-human acti-
vated caspase 3 FITC (1:100; BD Pharmingen) and (ii) mouse anti-PIV1 HN
(1:2,000 dilution of a 1:1 mix of HPIV1 HN 8.2.2.A and HPIV1 HN 4.5). Staining
was performed for 45 min at RT in a dark environment, and then cells were
rinsed twice with 2 ml FACS buffer and stained with allophycocyanin-conjugated
goat anti-mouse IgG (1:1,000; Jackson ImmunoResearch Laboratories, West
Grove, PA) diluted in FACS buffer containing 0.1% Triton X-100. Staining was
carried out for 30 min at RT. Finally, cells were rinsed twice in FACS buffer and
resuspended in 250 l FACS buffer for analysis. Sample analysis was carried out
on a FACSCalibur (BD Biosciences, San Jose CA) using CellQuestPro soft-
ware. Further analysis was performed using FlowJo software (TreeStar, Inc.,
Ashland, OR).
Type I IFN bioassay. The amount of type I IFN produced by HPIV1-infected
A549 cell cultures was determined by an IFN bioassay, as previously described
(65). Type I IFN concentrations were determined by measuring the ability of
samples of the cell cultures to restrict replication of VSV-GFP on HEp-2 cell
monolayers in comparison to a known concentration of a human beta interferon
(IFN-) standard (Avonex; Biogen, Inc., Cambridge, MA). Briefly, samples were
treated at pH 2.0 to inactivate virus and acid-labile type II IFN prior to being
serially diluted 10-fold in duplicate in 96-well plates of HEp-2 cells along with the
IFN- standard (5,000 pg/ml). After 24 h, the cells were infected with VSV-GFP
at 6.5  104 PFU/well. After an additional 24 to 36 h, plates were read for GFP
expression by using a Typhoon 8600 phosphorimager (Molecular Dynamics,
Sunnyvale, CA). The dilution at which the level of GFP expression was approx-
imately 50% of that in untreated cultures was determined as the end point. The
end point of the Avonex standard was compared to the end point of the unknown
samples, and IFN concentrations were determined and expressed as mean 
standard error (SE) (pg/ml).
Evaluation of replication of viruses in hamsters and efficacy against challenge.
Four- to 6-week-old Syrian golden hamsters in groups of five or six per virus were
inoculated intranasally (i.n.) with 0.1 ml of Leibovitz’s L-15 medium (Gibco-
Invitrogen) containing 105.5 TCID50 of wt rHPIV1, rHPIV1-P(C), or control
(L-15 only) inoculum. On days 4 and 5 p.i, the nasal turbinates and lungs were
collected as previously described (50). Virus present in the tissue homogenates
was quantified by titration on LLC-MK2 monolayers. Infected cells were de-
tected on day 7 p.i. by hemadsorption with guinea pig erythrocytes. The mean
titer (log10 TCID50/g tissue) was calculated for each group of hamsters. The limit
of detection was 1.5 log10 TCID50/g. On day 28 p.i., hamsters that had been
previously immunized were challenged i.n. with 106 TCID50 of wt HPIV1 in 0.1
ml L-15. The nasal turbinates and lungs were collected for virus quantitation on
day 4 p.i.
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Evaluation of replication of viruses in AGMs and efficacy against challenge.
AGMs in groups of two to four animals at a time were inoculated i.n. and
intratracheally (i.t.) with 106 TCID50 of either wt HPIV1 or mutant rHPIV1 in
a 1-ml inoculum at each site. Nasopharyngeal (NP) swab samples were collected
daily from days 0 to 10 p.i., and tracheal lavage (TL) fluid samples were collected
on days 2, 4, 6, 8, and 10 p.i. The specimens were flash frozen and stored at
80°C until they were assayed in parallel. Virus present in the samples was
titered in serial dilutions on LLC-MK2 cell monolayers in 96-well plates, and an
undiluted 100-l aliquot was also tested in 24-well plates. Following incubation
for 7 days, virus was detected by hemadsorption, and the mean log10 TCID50/ml
titer was calculated for each sample day. The limit of detection was 0.5 log10
TCID50/ml. The mean peak titer for each group was calculated by using the peak
titer for each animal, irrespective of the day of sampling. On day 28 p.i., the
AGMs were challenged i.n. and i.t. with 106 TCID50 of wt HPIV1 in 1 ml L-15
per site. NP swab and TL samples were collected for virus quantitation on days
2, 4, 6, and 8 postchallenge.
All animal studies were performed under protocols approved by the National
Institute of Allergy and Infectious Disease (NIAID) Animal Care and Use
Committee (ACUC).
Viral inoculation of HAE. The apical surfaces of HAE were rinsed with PBS
to remove apical surface secretions and fresh medium was supplied to the
basolateral compartments prior to inoculation. The apical surfaces of HAE were
inoculated with HPIV1s at a low input MOI (0.01 TCID50/cell) in a 100-l
inoculum, and the cultures were incubated at 37°C. The inoculum was removed
2 h p.i., and the apical surfaces rinsed for 5 min with PBS and then incubated at
37°C. At days 0 to 7 p.i., apical samples were collected by incubating the apical
surface with 300 l of medium for 30 min at 37°C, after which the medium was
recovered. Samples were stored at 80°C prior to determination of virus titer.
Statistical analysis. The Prism 5 (GraphPad Software, Inc., San Diego, CA)
one-way analysis of variance test (Student-Newman-Keuls multiple compar-
ison test) was used to assess statistically significant differences between data
groups (P  0.05).
RESULTS
Construction and recovery of an rHPIV1 mutant not ex-
pressing any of the four C proteins. The P/C gene of wt HPIV1
encodes the phosphoprotein, P, in one ORF and four carboxy-
coterminal C proteins, C, C, Y1, and Y2, in a second, over-
lapping ORF (Fig. 1A). We engineered rHPIV1 to silence the
expression of all four C proteins without affecting the P pro-
tein, creating the mutant virus rHPIV1-P(C) (Fig. 1B and C).
The changes introduced to silence the expression of the C
proteins included the deletion of the 3 portion of the P/C gene
containing the C start, conversion of the C start to an ACG
codon, and the introduction of three stop codons into the C
ORF immediately downstream of the Y1 and Y2 start codons
(Fig. 1B and C). Importantly, all of the introduced changes
were silent in the P protein (Fig. 1B and C). The Y1 and Y2
start codons were not modified since any changes introduced at
these sites would have altered P protein amino acid assign-
ments. The AUG-to-ACG change at the start site of C would
not necessarily silence its expression entirely, since ACG func-
tions (inefficiently) as a start codon for the C protein of SeV,
but other changes at this site could not be accommodated
without affecting P coding, and in any event, any residual
expression of C would be ablated by the three stop codons that
were introduced downstream. The recombinant virus was re-
covered from this mutant cDNA in cell culture, and the virus
replicated to 8.0 log10 TCID50/ml. Sequence analysis of the
entire virus genome revealed that rHPIV1-P(C) contained
all the intended mutations and no unintended changes (data
not shown).
The results of Western blot analysis of infected LLC-MK2
cell lysates using an antibody directed against the carboxy
terminus of the C proteins demonstrated the expression of the
C and C proteins in cells infected with wt HPIV1, but not
rHPIV1-P(C) (Fig. 2A). C was found to be the most abun-
dant C protein, and Y1 and Y2 were not detected. An addi-
tional unidentified species, indicated with an asterisk in Fig.
2A, was detected in cells infected with rHPIV1-P(C), but not
in cells infected with wt rHPIV1 (Fig. 2A). This species was not
detected by using an antibody directed against the amino ter-
minus of the C and C proteins (data not shown). An ATG
codon in the C ORF that is downstream of the last inserted
stop codon in Y2 could potentially give rise to a truncated
FIG. 2. Identification of HPIV1 C and P proteins in lysates from infected LLC-MK2 cells. Lysates were prepared 48 h p.i. from LLC-MK2 cells
that were mock infected or infected with sucrose-purified wt rHPIV1 or rHPIV1-P(C) at an input MOI of 5 TCID50/cell. Reduced, denatured
cell lysates were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western blots were prepared and analyzed by using
rabbit antipeptide antisera against the HPIV1 C proteins (A) and the HPIV1 P protein (B). The asterisk in panel A indicates a new band of
unknown identity, detected only in the rHPIV1-P(C)-infected cell lysates.
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protein that would be carboxy coterminal with the C proteins
and would be 157 aa in length, compared to 204 aa for the C
protein and 175 aa for Y2 (Fig. 1A). This 47-aa difference in
predicted size between C and the unknown protein in Fig. 2A
would correspond to an approximately 5-kDa difference in the
proteins’ apparent molecular masses, consistent with the
mobility difference observed in our Western blot (Fig. 2A).
The P protein could be detected in both wt rHPIV1- and
rHPIV1-P(C)-infected cells (Fig. 2B). The ability to re-
cover the rHPIV1-P(C) mutant indicates that the four wt
C proteins are not essential for replication in vitro, with the
caveat that there was expression of a new species that may
have been a truncated C protein.
The rHPIV1-P(C) mutant replicates efficiently in vitro but
causes increased CPE compared to wt rHPIV. Multicycle rep-
lication of the rHPIV1-P(C) mutant was assessed in LLC-
MK2 cells infected at an MOI of 0.01 TCID50/cell (Fig. 3A).
LLC-MK2 cells were chosen since wt HPIV1 replicates effi-
ciently in this cell line. rHPIV1-P(C) and wt rHPIV1 repli-
cated to similar titers until day 3 p.i., when wt rHPIV1 contin-
ued to increase in titer, whereas rHPIV1-P(C) decreased in
titer. Concomitantly, rHPIV1-P(C)-infected LLC-MK2 cells
developed extensive CPE, while wt rHPIV1-infected cells did
not (Fig. 3B). This also is evident in photomicrographs of
LLC-MK2 cells taken 72 h following infection at MOIs of 0.01
or 5 TCID50/cell (Fig. 3B). In LLC-MK2 cells infected at an
MOI of 5 TCID50/cell, increased CPE associated with rHPIV1-
P(C), but not wt rHPIV1, became evident at approximately
48 h p.i. (data not shown). Similarly, enhanced CPE associated
with infection by the rHPIV1-P(C) mutant was observed in
A549 cells (data not shown), which were evaluated since they
are a human respiratory tract-derived continuous cell line and
in vivo HPIV1 replicates preferentially, if not exclusively, in
respiratory epithelial cells. In summary, rHPIV1-P(C) and wt
rHPIV1 replicated with equal efficiency early in infection, but
there was a subsequent decrease in rHPIV1-P(C) titers that
was temporally associated with the development of extensive
CPE, a phenomenon not seen in wt rHPIV1-infected cells.
Infection with rHPIV1-P(C) infection induces apoptosis.
To further explore the basis of the enhanced CPE associated
with the rHPIV1-P(C) mutant, we assayed virus-infected
LLC-MK2 cells for activation of caspase 3, the major effector
caspase in the apoptotic pathway. Activated caspase 3 was
visualized by immunofluorescence (Fig. 4A) and by FACS
analysis (Fig. 4B) using an antibody that specifically recognizes
the cleaved, activated form of the enzyme. Replicate LLC-
MK2 monolayers were infected at an MOI of 10 TCID50/cell;
incubated for 24, 48, and 72 h; fixed; permeabilized; and
stained with antibodies for HPIV1 HN (Texas Red) and for
activated caspase 3 (FITC). The HPIV1 HN antigen was de-
tected in the vast majority of cells infected with either virus
(Fig. 4A). By 72 h p.i., activated caspase 3 was detected in the
majority of the rHPIV1-P(C)-infected cells, but not wt
rHPIV1-infected cells (Fig. 4A). In addition, cell rounding
and nuclear condensation was seen in the majority of
rHPIV1-P(C)-infected cells, but not in wt rHPIV1-in-
fected cells (Fig. 4A), consistent with the interpretation that
the rHPIV1-P(C)-induced CPE is the direct result of vi-
rus-induced apoptosis.
We next determined the frequency of apoptosis in infected
cells by using flow cytometry. The rHPIV1-CF170S mutant,
which encodes an F170S substitution in C, and which has
previously been associated with type I IFN induction and ef-
fective type I IFN signaling, but not with CPE in vitro, was
included here for comparison. Replicate cultures of LLC-MK2
cells were infected with wt rHPIV1, rHPIV1-CF170S, or
rHPIV1-P(C) at an MOI of 5 TCID50/cell and, at 24, 48,
and 72 h p.i., were fixed, permeabilized, and immunostained
for HPIV1 HN protein and activated caspase 3 (Fig. 4B).
More than 70% of cells in the rHPIV1-P(C)-infected cul-
tures were positive for activated caspase 3 by 72 h p.i.,
compared to approximately 5% and 7% in the wt rHPIV1-
and rHPIV1-CF170S-infected cell cultures, respectively (Fig.
4C). The results of similar studies in Vero and A549 cells
confirmed that rHPIV1-P(C) was a potent activator of
caspase 3 activation, while wt rHPIV1 was not, although the
level of caspase 3 activation in these cells was lower than in
LLC-MK2 cells (data not shown). Vero cells were also evalu-
FIG. 3. Comparison of the replication of wt rHPIV1 and rHPIV1-
P(C) in vitro. (A) Multicycle replication in LLC-MK2 cells infected
at an MOI of 0.01 TCID50/cell. On days 0 to 7 p.i., the overlying
medium was harvested for virus titration, shown as the means  SE of
the results for three replicate cultures. On days 1 to 7 p.i., the cell
monolayers were monitored for CPE and assigned a score of 1 to 5
according to the extent of CPE (Materials and Methods), shown as the
means of the results for the three replicate cultures. (B) LLC-MK2
cells were mock-infected or infected with wt rHPIV1 or rHPIV1-
P(C) at an MOI of 0.01 or 5 TCID50/cell, as indicated in parentheses
below the virus names. Photomicrographs taken at 72 h p.i. show
increased CPE in the rHPIV1-P(C)-infected cultures (magnification,
10).
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ated here since vaccine viruses to be used in clinical trials are
prepared in this cell line, and therefore, it is important to
determine the growth characteristics of potential vaccine vi-
ruses in this cell line. By 72 h p.i., approximately 12% and 18%
of rHPIV1-P(C)-infected Vero and A549 cell cultures, re-
spectively, were positive for activated caspase 3, compared to
approximately 4% of wt rHPIV1-infected cell cultures for both
cell types.
rHPIV1-P(C), but not wt rHPIV1, induces type I IFN
production and signaling. HPIV1 C proteins have been shown
to inhibit production of and signaling by type I IFN (8, 65). We
have previously demonstrated that type I IFN was not detected
during infection of A549 cells with wt HPIV1 but was effi-
ciently produced in response to rHPIV1-CF170S (65). To de-
termine the relative effect of deleting all four C proteins on the
ability of HPIV1 to inhibit the type I IFN response, we infected
A549 cells at an MOI of 5 TCID50/cell with rHPIV1-P(C), wt
rHPIV1, or rHPIV1-CF170S and subsequently quantified type I
IFN in medium supernatants by using a bioassay based on the
inhibition of infection and GFP expression by VSV-GFP (Fig.
FIG. 4. Infection with rHPIV1-P(C) induces activation of caspase 3, indicative of apoptosis. Caspase 3 activation was evaluated by immu-
nostaining and FACS analysis. (A) Evaluation of caspase 3 activation by immunofluorescence. LLC-MK2 cells were mock infected or infected with
wt rHPIV1 or rHIV1-P(C) at an MOI of 10 TCID50/cell. At 72 h p.i., cells were fixed, permeabilized, and stained for HPIV1 HN protein (red)
and activated caspase 3 (green), and nuclei were stained with DAPI (blue). The asterisk indicates cell rounding and nuclear condensation seen in
the majority of rHPIV1-P(C)-infected cells, but not in wt rHPIV1-infected cells. Cells were visualized by confocal microscopy, and scale bars
represent 10 m. (B) Evaluation of caspase 3 activation by FACS analysis. LLC-MK2 cells were mock infected or infected with wt rHPIV1,
rHPIV1-CF170S, or rHPIV1-P(C) at an MOI of 5 TCID50/cell in triplicate. Cells were harvested at 24, 48, and 72 h p.i., fixed, permeabilized, and
stained for HPIV1 HN and activated caspase 3 in FACS buffer prior to analysis. Sample analysis was carried out by using a FACSCalibur flow
cytometer and FlowJo software. Dot plots of representative data for samples from the 48-h time point are shown. The frequency of events is
indicated for each quadrant (% total events). APC, allophycocyanin. (C) Percentages of cells positive for activated caspase 3 at 24, 48, and 72 h
p.i., as determined by FACS analysis. Error bars show SE.
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5A). As shown previously, wt rHPIV1 inhibited the IFN re-
sponse effectively (Fig. 5A), with barely detectable levels of
IFN- appearing late in infection, at 72 h p.i. In contrast, both
rHPIV1-P(C) and rHPIV1-CF170S induced a robust type I
IFN response, with IFN detectable in the supernatant as early
as 24 h p.i. and until 72 h p.i., achieving a peak concentration
of approximately 300 pg/ml at 48 h p.i. These data suggest that
C proteins play a critical role in antagonism of type I IFN
production but that IFN generation is unrelated to the apop-
totic response seen with the C mutants, since the F170S mutant
generates similar levels of IFN with no observable CPE beyond
that of wt HPIV1.
We have previously demonstrated that type I IFN signaling
leading to the establishment of an antiviral state is inhibited
following infection with wt HPIV1, but not with mutants that
encode defective C proteins, e.g., rHPIV1-CF170S (65). To de-
termine the relative effect of deleting all four C proteins on the
ability of HPIV1 to inhibit type I IFN signaling, Vero cells
were mock infected or infected with wt rHPIV1, rHPIV1-
CF170S, or rHPIV1-P(C) at an MOI of 5 TCID50/cell for 24 h,
treated with 0, 100, or 1,000 IU of IFN- for 24 h, and infected
with 200 PFU/well of VSV-GFP. The number of VSV-GFP
foci were counted 48 h later, and the percent inhibition due to
IFN- treatment was calculated relative to the inhibition in
cells that did not receive IFN- (Fig. 5B). In control cells that
were not infected with rHPIV1, VSV-GFP replication was
completely inhibited by IFN- treatment. In contrast, infection
with wt rHPIV1 ablated the ability of 100 IU/ml of IFN- to
inhibit VSV-GFP replication and blunted the inhibitory effect
of 1,000 IU/ml of IFN-, indicating that wt rHPIV1 can pre-
vent IFN- signaling and the induction of an antiviral state.
Infection with rHPIV1-P(C) did not inhibit the antiviral ef-
fect of IFN- at either concentration, an effect similar to that
for rHPIV1-CF170S (Fig. 5B). In summary, unlike wt rHPIV1,
rHPIV1-P(C) is unable to inhibit both the production of type
I IFN and the induction of an antiviral state by IFN-.
rHPIV1-P(C) is highly attenuated in hamsters and con-
fers protection against wt HPIV1 challenge. Golden Syrian
hamsters were inoculated i.n. with 105.5 TCID50 of rHPIV1-
P(C) or wt rHPIV1. Animals were sacrificed on days 4 and
5 p.i., and the level of virus replication in nasal turbinates and
lungs was quantified by virus titration. In comparison to titers
of wt rHPIV1, rHPIV1-P(C) was restricted approximately
1,000-fold in the upper respiratory tract (URT) and 250-fold in
the lower respiratory tract (LRT) on both sampling days (Ta-
ble 1). Although the replication of rHPIV1-P(C) was highly
restricted in hamsters, the animals were protected against i.n.
challenge with 106 TCID50 of wt HPIV1 28 days postvaccina-
tion (Table 2). The replication of challenge virus in rHPIV1-
P(C)-immunized hamsters was restricted 200-fold in the
URT and 16-fold in the LRT compared to these levels of
replication in nonimmunized hamsters. Previous infection with
wt rHPIV1 restricted the replication of challenge virus even
better than rHPIV1-P(C), reducing challenge virus titers
1,000-fold in the URT and 160-fold in the LRT (Table 2).
rHPIV1-P(C) is highly attenuated in AGMs and confers
protection against wt HPIV1 challenge. The attenuation phe-
TABLE 1. Replication of rHPIV1-P(C) in the URT and
LRT of hamstersa
Virus
Mean virus titer (log10 TCID50/g)  SEb
Nasal turbinates on day Lungs on day
4 5 4 5
Wt rHPIV1c 5.2  0.2 (10) 5.3  0.4 (11) 4.6  0.2 (10) 4.6  0.4 (11)
rHPIV1-P(C) 2.0  0.2d (5) 2.2  0.2d (5) 2.2  0.2d (5) 2.2  0.1d (5)
a Hamsters were inoculated i.n. with 105.5 TCID50 of the indicated virus.
b The limit of detection was 1.5 log10 TCID50/g. The number of animals per
group is indicated in parentheses.
c The data for the wt rHPIV1 group represent the results of two independent
experiments.
d There was a statistically significant reduction in virus titer compared to that
of the rHPIV1 wt group at the same time point (P  0.001; Student-Newman-
Keuls multiple-comparison test).
FIG. 5. Wt rHPIV1, but not rHPIV1-P(C), inhibits type I IFN
induction and signaling. (A) Induction of type I IFN. A549 cell mono-
layers were either mock infected or infected with wt rHPIV1, rHPIV1-
CF170S, or rHPIV1-P(C) at an MOI of 5 TCID50/cell. Aliquots of the
overlying medium were taken at 0, 24, 48, and 72 h p.i. and assayed on
fresh cells for the ability to inhibit infection and GFP expression by
VSV-GFP as measured with a phosphorimager. IFN concentrations
were determined by comparison with a standard curve prepared in
parallel with an Avonex IFN- standard and are expressed in pg/ml 
SE based on the results for triplicate samples. The lower limit of
detection was 39.1 pg/ml (dashed line). (B) Type I IFN signaling. Vero
cells in six-well plates were infected with the indicated rHPIV1 at an
MOI of 5 TCID50/cell and incubated for 24 h. Cells were then left
untreated or were treated with 100 or 1,000 IU/ml IFN- (one well per
treatment per virus) for 24 h. The cells were then infected with VSV-
GFP and incubated for 48 h. The VSV-GFP foci were visualized by
using a phosphorimager and counted. The graph represents the per-
cent inhibition of VSV-GFP replication in IFN--treated versus un-
treated cells based on the results of two independent experiments.
Error bars show SE.
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notype of rHPIV1-P(C) was also evaluated in AGMs. Fol-
lowing i.n. and i.t. inoculation of AGMs with 106 TCID50 of
rHPIV1-P(C) or wt HPIV1 at each site, virus titers were
determined in NP swab samples (representative of the URT)
on days 0 to 10 p.i. and TL samples (representative of the
LRT) on days 2, 4, 6, 8, and 10 p.i. Wt HPIV1 replication was
robust in both the URT and the LRT of AGMs, with continued
replication through day 10 p.i. (Fig. 6) and mean peak virus
titers of 3.7 and 3.3 log10 TCID50/ml in the URT and LRT,
respectively. In contrast, rHPIV1-P(C) replication was unde-
tectable in the URT and restricted but detectable in the LRT
(Fig. 6). The level of replication of rHPIV1-P(C) was com-
pared with that of the previously described rHPIV1-CF170S (1),
a mutant that shares the IFN induction phenotype of rHPIV1-
P(C) but, as shown above, differs from rHPIV1-P(C) in
that it does not induce apoptosis. rHPIV1-P(C) was found to
be more attenuated than rHPIV1-CF170S, and the difference in
viral load between the two vaccination groups over time is
indicated in Fig. 6. Despite its restricted replication, rHPIV1-
P(C) provided AGMs with protection against i.n. and i.t.
challenge with 106 TCID50 wt HPIV1 per site at 28 days p.i.
(Table 3). The replication of the wt HPIV1 challenge virus was
restricted by approximately 100-fold in the URT and the LRT
of rHPIV1-P(C)-immunized monkeys compared to its levels
of replication in nonimmunized monkeys (Table 3).
Replication of rHPIV1-P(C) is restricted in HAE cells in
vitro. Wt HPIV1 has previously been shown to infect ciliated
HAE cells in an in vitro model of the HAE (4). Here, we
characterized the ability of rHPIV1-P(C) to infect HAE in a
multiple-cycle growth curve. Following apical inoculation at a
low input MOI (0.01 TCID50/cell), wt rHPIV1 replicated effi-
ciently in HAE, reaching a peak titer of 7.4 log10 TCID50/ml in
the apical wash fluid. However, the replication of rHPIV1-P(C)
was severely restricted in human ciliated cells, reaching a
barely detectable peak of 1.8 log10 TCID50/ml (Fig. 7).
DISCUSSION
The mutant rHPIV1-P(C), which does not express any of
the four wt C proteins but does express a wt P protein, was
generated and characterized in vitro and in vivo. rHPIV1-
P(C) was found to replicate efficiently in vitro, implying that
the HPIV1 C proteins are nonessential accessory proteins.
However, rHPIV1-P(C) expressed a novel protein not seen
with rHPIV1 that may have been a truncated form of C, and
thus, we cannot yet conclude that C-related proteins are com-
pletely dispensable. rHPIV1-P(C) replicated with the same
efficiency as wt HPIV1 early after infection of human- and
monkey-derived cell lines, but its replication subsequently de-
creased coincident with the onset of extensive CPE that was
not observed with wt rHPIV1. The C proteins of SeV have
been extensively characterized as nonessential gene products
with multiple functions (39, 41, 42). However, SeV and HPIV1
differ with regard to the genetic organization of their accessory
proteins and the phenotypes specified by accessory protein
mutations. First, SeV encodes a V protein in addition to the C
proteins, whereas HPIV1 does not (33). Second, deletion of all
four C proteins in SeV significantly restricted its replication in
vitro (23, 39, 41), whereas loss of the wt forms of all four
HPIV1 C proteins did not appear to reduce the replication
efficiency of rHPIV1-P(C) apart from the indirect effect of its
enhanced CPE. Third, a 6-aa deletion in the N-terminal region
FIG. 6. rHPIV1-P(C) is attenuated for replication in both the
URT and LRT of AGMs. Groups of AGMs were inoculated i.n. and
i.t. with 106 TCID50 of wt HPIV1 (n 	 16) or rHPIV1-P(C) (n 	 4)
per site. Previously published data for rHPIV1-CF170S (n 	 4) are also
included for comparison (2). Mean daily virus titers  SE in NP swabs
(representative of the URT) (A) and TL fluid (representative of the
LRT) (B) were determined for each sampling day (see Materials and
Methods; the limit of detection is 0.5 log10 TCID50/ml). The area
shaded in gray represents the additional reduction in replication ob-
served for rHPIV1-P(C) compared to that of rHPIV1-CF170S.
TABLE 2. Protection against wt HPIV1 challenge in hamsters
following immunization with rHPIV1-P(C)a
Immunizing virus or
L-15 medium
Mean HPIV1 challenge virus titer
(log10 TCID50/g)  SEb
Nasal turbinates Lungs
Wt rHPIV1 1.5  0.0c 1.7  0.2c
rHPIV1-P(C) 2.2  0.3c 2.7  0.2c
Control 4.5  0.2 3.9  0.4
a Hamsters were inoculated i.n. with 105.5 TCID50 of the indicated virus and
challenged on day 28 p.i. with 106 TCID50 of wt HPIV1 i.n. There were five
animals in each group.
b The limit of detection was 1.5 log10 TCID50/g. Nasal turbinates and lungs
from each group were harvested on day 4 postchallenge.
c There was a statistically significant reduction in virus titer compared to that
of the control group at the same time point (P  0.01; Student-Newman-Keuls
multiple-comparison test).
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of the SeV C protein had a profound effect on replication in its
natural host, i.e., rodents (15), whereas a similar mutation in
HPIV1 C did not affect replication in nonhuman primates, the
closest available animal model to its natural human host (1).
Fourth, the F170S mutation in SeV C induced apoptosis in
primary mouse pulmonary epithelial cells (29), whereas the
same mutation in HPIV1 failed to specify this phenotype in the
present study. Since the genetic organization of the accessory
proteins of SeV and HPIV1 differ and since the phenotypes of
C protein mutants differ significantly in vitro and in vivo, the
functions of the HPIV1 C proteins cannot be reliably inferred
from findings obtained with SeV C protein mutants, and there-
fore, they must be determined directly. An amino acid align-
ment of the HPIV1 and SeV C proteins is provided in Fig. 8.
In the case of HPIV1, this information has added importance
since live attenuated vaccine candidates that are presently be-
ing prepared for clinical trials include mutations in the C pro-
tein.
Replication of rHPIV1-P(C) in cell culture peaked early
and then decreased steadily, coincident with the development
of extensive CPE that was not observed with wt HPIV1. This
CPE was associated with caspase 3 activation, cell rounding,
nuclear condensation, and nuclear fragmentation, indicating
that it was apoptotic in nature. For this report, we identified a
novel protein expressed by rHPIV1-P(C), and therefore,
there is also the alternative possibility—albeit unlikely—that
the observed apoptosis during infection with rHPIV1-P(C)
was a gain-of-function due to the novel protein. However, in
other work in progress, we have generated additional HPIV1
mutants that also express this novel protein but do not induce
apoptosis and do not specify an attenuation phenotype (data
not shown). This indicates that the absence of the four C
proteins, and not the presence of the additional protein, is
associated with the apoptosis-inducing (and also the attenua-
tion) phenotypes of rHPIV1-P(C). Taken together, our data
indicate that one function of the HPIV1 C proteins is to delay
or prevent the apoptotic response of the infected cell. Apop-
tosis has also previously been associated with SeV C protein
mutants. SeV C deletion mutants have been shown to induce
apoptosis in vitro, whereas wt SeV did not (29, 39), suggesting
that both SeV C proteins and HPIV1 C proteins act as inhib-
itors of apoptosis. In addition, the SeV mutant Ohita MVC11,
containing the CF170S substitution, was observed to induce cell
death in vitro, while wt SeV did not (29). Similar to our ob-
servations of rHPIV1-P(C), Ohita MVC11 titers peaked
early and decreased concomitant with the induction of apop-
tosis (29). However, data we have presented suggest that de-
spite the relatively high degree of amino acid conservation
(70% identity) between HPIV1 and SeV C proteins (Fig. 8),
the induction of apoptosis and/or virus-mediated inhibition of
apoptosis may be mediated by different mechanisms for
HPIV1 and SeV C proteins. For example, although SeV Ohita
MVC11 induces apoptosis, the HPIV1 mutant containing the
homologous CF170S substitution, rHPIV1-CF170S, does not in-
duce apoptosis. Furthermore, IRF-3 activation was recently
shown to be required for apoptosis during SeV infection in
human cell lines (52), but we have previously shown that
rHPIV1-CF170S, which does not induce apoptosis, stimulates
TABLE 3. Protection against wt HPIV1 challenge in AGMs
following immunization with rHPIV1-P(C)a
Immunizing virus No. of animals
Mean peak titer (log10
TCID50/ml)  SEb
NP swabc TL fluidd
Wt HPIV1 14 0.9  0.2e 0.8  0.1e
rHPIV1-P(C) 4 2.8  0.5e 2.3  0.4e
Mock immunized 14 4.7  0.3 4.4  0.4
a Monkeys were inoculated i.n. and i.t. with 106 TCID50 of the indicated virus
in a 1-ml inoculum at each site. On day 28 p.i., monkeys were challenged i.n. and
i.t. with 106 TCID50 wt HPIV1 in a 1-ml inoculum at each site.
b The limit of detection was 0.5 log10 TCID50/ml.
c NP samples were collected on days 0, 2, 4, 6, and 8 postchallenge. The titers
on day zero were 0.5 log10 TCID50/ml.
d TL samples were collected on days 2, 4, 6, and 8 postchallenge.
e There was a statistically significant reduction in virus titer compared to that
of the nonimmunized group at the same time point (P  0.001; Student-New-
man-Keuls multiple-comparison test).
FIG. 7. rHPIV1-P(C) replicates very poorly in primary HAE
cells compared to the replication of wt rHPIV1. HAE cultures were
inoculated on the apical surface with the indicated virus at an MOI
of 0.01 TCID50/cell, and virus titers in apical surface washes were
determined at days 0 to 7 p.i. The results for triplicate cultures from
two donors are shown as the means  SE, and the limit of detection
is 1.2 log10TCID50/ml.
FIG. 8. CLUSTAL W alignment of the C protein amino acid se-
quences of SeV (Sendai C) and HPIV1 (GenBank accession numbers
NP_056874 and NP_604436, respectively). The alignment was gener-
ated by using the MacVector software program (MacVector, Inc.,
Cary, NC), using default parameters. Conserved amino acids are indi-
cated with asterisks.
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IRF-3 activation (65). Studies to define the mechanism of
apoptosis inhibition by HPIV1 have been initiated.
The most extensively characterized function of paramyxovi-
rus C proteins is their type I IFN antagonist activity. HPIV1 C
proteins have been shown to disrupt the host type I IFN re-
sponse by (i) inhibiting IRF-3 activation and thereby inhibiting
the production of type I IFN and (ii) inhibiting STAT nuclear
translocation (8) and thereby inhibiting the JAK-STAT signal-
ing pathway (65). Our results support these previous findings
by demonstrating that, in the absence of C proteins, type I IFN
is produced in response to HPIV1 infection and is able to
successfully establish an antiviral state in respiratory epithelial
cells. In contrast, infection with wt HPIV1 inhibits type I IFN
production, as well as the establishment of an antiviral state
that results from the activation of the JAK-STAT pathway (18,
21, 43, 57, 63, 68). This pathway controls the transcription of a
group of more than 300 genes termed the IFN-stimulated
genes, which have antiviral, antiproliferative, immunomodula-
tory, and apoptosis-modulating functions (43). Therefore, it is
not surprising that many viral proteins that have been charac-
terized as IFN antagonists have also been identified as playing
a role in the regulation of apoptosis. Examples of such proteins
include the Bunyamwera virus NSs proteins (35, 67), the RSV
NS1 and NS2 proteins (6, 60), and the influenza A virus NS1
protein (58, 62, 66, 73). Our data demonstrate that the HPIV1
C proteins also act both as type I IFN antagonists and as
apoptosis antagonists. Interestingly, however, the anti-IFN and
antiapoptosis activities of the HPIV1 C proteins were separa-
ble: while the rHPIV1-P(C) and rHPIV1-CF170S mutants
were indistinguishable with regard to the induction of IFN
production and signaling in cell culture, only rHPIV1-P(C)
induced apoptosis.
Since the type I IFN response and apoptosis are both com-
ponents of the host’s innate antiviral response, viruses that
have lost the ability to inhibit these responses are often atten-
uated in vivo. The attenuation phenotype of rHPIV1-P(C)
was evaluated in two in vivo models, i.e., in hamsters and
AGMs, and an in vitro model of ciliated HAE. The replication
of rHPIV1-P(C) was restricted more than 1,000-fold in the
URT and 250-fold in the LRT of hamsters following i.n. inoc-
ulation. Despite this high degree of attenuation, it induced
substantial protection against challenge with wt HPIV1: chal-
lenge virus replication was restricted 200-fold in the URT and
15-fold in the LRT. rHPIV1-P(C) was also evaluated in
AGMs to determine its potential for use as a live attenuated
pediatric vaccine against HPIV1; AGMs are a more-appropri-
ate model, since they are evolutionarily and anatomically
closer to humans than are hamsters. In AGMs, replication of
rHPIV1-P(C) was not detectable in the URT and was barely
detectable in the LRT. Despite this very high level of attenu-
ation, challenge virus titers were reduced 79- and 125-fold in
the URT and LRT, respectively. It is possible that rHPIV1-
P(C) will replicate more efficiently (and thus be more immu-
nogenic and protective) in humans than in AGMs since it is a
human virus that is more permissive in its natural host. For
example, while HPIV1 causes significant respiratory disease in
humans, infection of AGMs is asymptomatic.
In order to obtain an independent assessment of attenuation
prior to the initiation of clinical trials, the replication of
rHPIV1-P(C) was characterized in a HAE model, which uses
primary HAE cells grown at an air-liquid interface to generate
a differentiated, pseudostratified, ciliated epithelium that bears
close structural and functional similarity to HAE in vivo (53,
72). A similar model has been used previously to evaluate the
attenuation of RSV vaccines (70). We have also recently char-
acterized the replication of wt HPIV1 and several HPIV1
vaccine candidates in the in vitro HAE model and observed a
strong correlation between attenuation in AGMs and attenu-
ation in HAE cells, indicating the potential usefulness of the
HAE model for evaluating potential respiratory virus vaccine
candidates (4). In our current HPIV1 study, the growth of
rHPIV1-P(C) in HAE cells was barely detectable, whereas
wt rHPIV1 grew to high titers. Since rHPIV1-P(C) is highly
restricted in replication in AGMs and in HAE cells, previous
observations that the level of replication in HAE cells mimics
the level of replication in AGMs were confirmed, thus provid-
ing further evidence of the utility of the in vitro HAE model.
This also suggests that this virus might be overattenuated in
humans, potentially limiting its efficacy as a vaccine. Therefore,
we are currently proceeding to clinical trials with a previously
characterized virus, rHPIV1-CR84G/
170HNT553ALY942A (3),
that is less attenuated than rHPIV1-P(C) in AGMs. Only if
rHPIV1-CR84G/
170HNT553ALY942A proves to be insufficiently
attenuated will we advance rHPIV1-P(C) into clinical trials.
The results of previous studies of rHPIV1 C mutants dem-
onstrated that in vivo attenuation correlated with the ability to
stimulate an effective type I IFN response, including IFN pro-
duction and IFN signaling (1, 65). This was demonstrated in
detail for rHPIV1-CF170S (65). The rHPIV1-P(C) virus was
indistinguishable from rHPIV1-CF170S with regard to the in-
duction of type I IFN production and signaling to establish an
antiviral state in vitro. However, rHPIV1-P(C) was much
more attenuated in AGMs than rHPIV1-CF170S. This in-
creased level of attenuation might be due to the induction of
apoptosis by rHPIV1-P(C), a property not shared by
rHPIV1-CF170S. We did not determine whether apoptosis was
induced in vivo following rHPIV1-P(C) infection; however,
an SeV mutant containing the CF170S mutation was shown to
induce apoptosis both in vitro and in vivo in the bronchial
epithelium of mice, and this virus was also attenuated in its
natural host (16, 29). It is possible that the in vitro apoptosis
phenotype of rHPIV1-P(C) can translate to in vivo effects.
This would suggest that the greater level of in vivo attenuation
of rHPIV1-P(C) than of rHPIV1-CF170S is based on two
additive effects: (i) the ability (of both viruses) to activate the
type I IFN response and (ii) the ability of rHPIV1-P(C) (but
not PIV1-CF170S) to induce apoptosis. The results shown in
Fig. 6 highlight this added degree of attenuation that could be
due to the induction of apoptosis. However, it is also possible
that a C protein function other than inhibition of the IFN
response and apoptosis contributed to the high level of atten-
uation of rHPIV1-P(C) in AGMs.
In summary, we have demonstrated that the HPIV1 C pro-
teins are nonessential viral proteins that play an important role
in viral replication in vitro and in vivo and act as antagonists
of the type I IFN response and of apoptosis. Our HPIV1 C
protein deletion mutant is highly attenuated in nonhuman
primates and in primary HAE, yet this virus does confer
significant protection against wt HPIV1 challenge in vivo. It
remains to be determined whether such a highly attenuated
VOL. 82, 2008 HPIV1 C PROTEINS REGULATE TYPE I IFN AND APOPTOSIS 8975
virus would be useful as a vaccine candidate against PIV1 in
humans.
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